Get the Stockscreener App
4.99
0.80%
-0.04
After Hours:
5.08
0.09
+1.80%
Kalaris Therapeutics Inc stock is traded at $4.99, with a volume of 108.59K.
It is down -0.80% in the last 24 hours and down -24.85% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$5.03
Open:
$5.08
24h Volume:
108.59K
Relative Volume:
0.34
Market Cap:
$93.33M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.67%
1M Performance:
-24.85%
6M Performance:
-14.41%
1Y Performance:
+0.00%
1-Day Range:
$4.78
$5.45
1-Week Range:
$4.70
$5.45
52-Week Range:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
628 MIDDLEFIELD ROAD, PALO ALTO
Compare KLRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
4.99 | 94.07M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
Kalaris Therapeutics Inc Stock (KLRS) Latest News
KLRS Sees New Analyst Rating: Citizens Initiates with Market Out - GuruFocus
Tools to assess Kalaris Therapeutics Inc.’s risk profileMarket Volume Report & Safe Swing Trade Setups - newser.com
Can trapped investors hope for a rebound in Kalaris Therapeutics Inc.Bull Run & Real-Time Chart Breakout Alerts - newser.com
Kalaris Therapeutics appoints Matthew Gall as chief financial officer By Investing.com - Investing.com UK
What MACD and RSI say about Kalaris Therapeutics Inc.Market Growth Review & Safe Swing Trade Setups - newser.com
Kalaris Therapeutics Appoints New CFO Matthew Gall - TipRanks
Kalaris Therapeutics appoints Matthew Gall as chief financial officer - Investing.com
Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer - The Manila Times
Kalaris (KLRS) names Matthew Gall CFO amid Phase 1b/2 nAMD study enrollment - Stock Titan
Analyzing Kalaris Therapeutics Inc. with risk reward ratio chartsJuly 2025 Sentiment & Stepwise Trade Execution Plans - newser.com
What’s next for Kalaris Therapeutics Inc. stock price2025 Short Interest & Target Return Focused Stock Picks - newser.com
Will Kalaris Therapeutics Inc. outperform the marketPortfolio Return Summary & Real-Time Volume Analysis Alerts - newser.com
Can Kalaris Therapeutics Inc. rally from current levelsJuly 2025 Analyst Calls & Community Verified Watchlist Alerts - newser.com
What to expect from Kalaris Therapeutics Inc. in the next 30 daysWatch List & Real-Time Volume Trigger Notifications - newser.com
Is Kalaris Therapeutics Inc. stock positioned for digital transformationQuarterly Earnings Summary & Capital Efficient Trading Techniques - newser.com
Citizens initiates Kalaris stock with Market Outperform rating, $20 price target - Investing.com
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Declines By 40.5% - MarketBeat
How resilient is Kalaris Therapeutics Inc. stock in market downturnsTrade Performance Summary & Safe Swing Trade Setups - newser.com
How Kalaris Therapeutics Inc. stock performs in rate cut cyclesWeekly Trend Report & Consistent Income Trade Ideas - newser.com
How to use a screener to detect Kalaris Therapeutics Inc. breakoutsJuly 2025 WrapUp & Weekly Watchlist of Top Performers - newser.com
Kalaris Therapeutics Inc. stock outlook for YEAR2025 Performance Recap & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-31 05:04:53 - newser.com
Identifying reversal signals in Kalaris Therapeutics Inc.Weekly Earnings Recap & Low Risk Investment Opportunities - newser.com
Kalaris to Present at Stifel 2025 Annual Healthcare Conference - Investing News Network
Kalaris (Nasdaq: KLRS) to present at Stifel Healthcare Conference; CEO & CMO 3:20–3:50 ET - Stock Titan
Leading vs lagging indicators on Kalaris Therapeutics Inc. performance2025 AllTime Highs & Safe Capital Growth Tips - newser.com
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
There is no financial data for Kalaris Therapeutics Inc (KLRS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):